Ann: Quarterly Activity Report and Appendix 4C for Q2 FY2022, page-37

Can we all just remind ourselves that XV LVAS is 4Dmedical CORE product, and the US is their PRIMARY market that worth $13 billion dollars. This product has been cleared and commercial roll out started in AUS but for whatever reasons they haven't signed any contracts in the US yet, maybe big investors still waiting for this to happen before they they jump in.

Rather than asking management for weekly updates on other products that are still in the making (Unless its a major milestone) as share holders i think we should be be focusing on XV LVAS commercialisation, ask management how to speed up the roll out etc, so company can start generating more revenue so hopefully they don't have to do CR more often and dilute SOI.

The quarterly update proved that management has been working in the back ground on all products. Regular non price sensitive announcements on ASX will cause more damage than good, management will loose credibility, or maybe distracting investors because theyre failing to deliver commercial plan, cause pump and dump etc.

Investors want to see weekly announcements on signing up more clinic, hospitals and thats where should be our focus on. Thats my opinion